ACTOS® (pioglitazone HCl) To Be Studied In New Trial Investigating Its Effects On Atherosclerosis In Patients With Type 2 Diabetes
New Results from the Landmark PROactive Trial Found That ACTOS® (pioglitazone HCl) Reduced the Occurrence of Major Adverse Cardiovascular Events
